Concepedia

Publication | Open Access

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

DOIFull Paper Access

114

Citations

8

References

2021

Year

Stephen L. Lowe, Brian A. Willis, Anne Hawdon, Fanni Natanegara, Laiyi Chua, Joanne Foster, Sergey Shcherbinin, Paul Ardayfio, John R. Sims
Alzheimer s & Dementia Translational Research & Clinical Interventions

Abstract

Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.

References

YearCitations

Page 1